Objectives: To assess the association between testosterone levels and APOEepsilon4 in cases with AD and controls.
Method: We included 61 men with definite or probable Alzheimer's disease (AD) and 55 elderly male controls from the Oxford Project to Investigate Memory and Ageing (OPTIMA). Testosterone was measured using a competitive enzyme immunoassay (Bayer).
Results: We found that both low serum testosterone and the interaction between testosterone and APOEepsilon4 were associated with AD. Furthermore, testosterone levels were lower in APOEepsilon4-positive controls (mean: 11.3 nmol/L) than in controls without the allele (19.1 nmol/L).
Conclusions: Low testosterone is potentially a modifiable risk factor, which may prove relevant to APOEepsilon4 carriers who are at risk of AD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/gps.714 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!